Physician profile
John J Riley
NPI 1932170610
$1,074.58
in general payments reported to CMS, 2019-2025
13 companies · $239 in 2025
The $239 reported for 2025 was more than what a typical Foot Surgery provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.09 · 2021: $51.28 · 2022: $42.26 · 2023: $332 · 2024: $339 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $909.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $339.93 | 2024-2025 | Evoke |
| Kerecis Limited | $307.83 | 2023-2025 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Kowa Pharmaceuticals America, INC. | $77.51 | 2023 | Seglentis |
| Stryker Corporation | $67.12 | 2019-2023 | Easyfuse, Augment Injectable, Citrefix |
| Paratek Pharmaceuticals, INC. | $52.71 | 2023 | Nuzyra |
| Organogenesis INC. | $51.28 | 2021 | |
| Amgen INC. | $39.56 | 2024-2025 | Krystexxa |
| Horizon Therapeutics Plc | $32.69 | 2019-2022 | |
| Ibsa Pharma INC. | $28.25 | 2023-2024 | Tirosint, Tirosint, Licart |
| Bioventus LLC | $26.41 | 2022 | |
| Treace Medical Concepts, INC. | $18.88 | 2024 | |
| Integra Lifesciences Corporation | $16.83 | 2019 | |
| Convatec INC. | $15.58 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Riley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.